FierceBiotech Radio Podcast
1) Pricing drugs, selling hype and how we got here in the first place
FierceBiotech chats with a pair of lawyers about how drug pricing is unique in the U.S. and how the biopharma environment lends itself to selling hype and securities fraud.
2) The FierceMadness drug name showdown and how do drugs get their zany names anyway?
Fierce editors discuss the FierceMadness drug name tournament, its origins, and our favorites heading into the competition. Scott Piergrossi of the Brand Institute talks us through the history of drug...Show More
The FierceMadness drug name showdown and how do drugs get their zany names anyway?
21:26 | Mar 13th, 2018
3) Back from the dead: FierceBiotech Radio at the Battle of the Biotech Bands
FierceBiotech sat down with some of the scientists, account associates and operations managers who competed in 2017's Battle of the Biotech Bands.
Back from the dead: FierceBiotech Radio at the Battle of the Biotech Bands
09:46 | Oct 31st, 2017
4) GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster
Fierce editors discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decision with a big Alzheimer's trial and Valeant Pharmaceuticals' rough week.
GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster
28:41 | Mar 18th, 2016
5) The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'
Fierce editors discuss the confirmation of Robert Califf as the next FDA commissioner, Sanofi's efforts to undercut Novo Nordisk in diabetes, and a novel approach to regulating drug costs.
The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'
41:26 | Feb 26th, 2016
6) Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals
Fierce editors discuss the rise of TV ads for specialty drugs, signs of life in the biotech IPO scene, and the case for Intercept Pharmaceuticals as a buyout target.
7) Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars
Fierce editors discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world of biosimilars.
8) Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover
Fierce editors discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the latest move in Sanofi's efforts to right the ship.
Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover
36:41 | Feb 4th, 2016
9) Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup
Fierce editors discuss Shire's increasingly complicated ambition to acquire Baxalta, the changing climate of biotech venture capital and the future of Valeant Pharmaceuticals.
10) The burning hole in Gilead's $25B pocket and AbbVie's future in hematology
Fierce editors discuss the discussion around Gilead Sciences' huge cash reserve and the many things the company might buy. Plus, a look back at AbbVie's blockbuster buyout of Pharmacyclics and a thoug...Show More
The burning hole in Gilead's $25B pocket and AbbVie's future in hematology
19:52 | Dec 10th, 2015